[
  {
    "ts": "2026-02-25T08:13:54+00:00",
    "headline": "Has Merck (MRK) Run Too Far After Its 41% Discount To Estimated Fair Value?",
    "summary": "If you are wondering whether Merck's share price still offers value after a strong run, you are not alone. This article is built to help you frame that question clearly. At a last close of US$123.93, Merck's stock has returned 1.9% over 7 days, 14.6% over 30 days, 16.4% year to date, 40.6% over 1 year, 27.8% over 3 years and 109.1% over 5 years. Recent attention on Merck has focused on its broader role in large cap pharmaceuticals, with investors regularly reassessing how its drug portfolio...",
    "url": "https://finance.yahoo.com/news/merck-mrk-run-too-far-081354474.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "257e67b9-0606-32da-ba22-8b47f4f8ba4b",
      "content": {
        "id": "257e67b9-0606-32da-ba22-8b47f4f8ba4b",
        "contentType": "STORY",
        "title": "Has Merck (MRK) Run Too Far After Its 41% Discount To Estimated Fair Value?",
        "description": "",
        "summary": "If you are wondering whether Merck's share price still offers value after a strong run, you are not alone. This article is built to help you frame that question clearly. At a last close of US$123.93, Merck's stock has returned 1.9% over 7 days, 14.6% over 30 days, 16.4% year to date, 40.6% over 1 year, 27.8% over 3 years and 109.1% over 5 years. Recent attention on Merck has focused on its broader role in large cap pharmaceuticals, with investors regularly reassessing how its drug portfolio...",
        "pubDate": "2026-02-25T08:13:54Z",
        "displayTime": "2026-02-25T08:13:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-run-too-far-081354474.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-run-too-far-081354474.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T09:10:00+00:00",
    "headline": "Merck & Co Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map",
    "summary": "Merck's market opportunities lie in its broad biopharmaceutical offerings, targeting oncology, vaccines, and more, alongside extensive veterinary solutions. Its tech-driven innovations, strategic partnerships, and global presence enhance its competitive edge in healthcare and digital transformation initiatives.Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The \"Enterprise Tech Ecosystem Series: Merck & Co., Inc. 2025\" company profile has been added to ResearchAndMarkets.com's offering. The report pro",
    "url": "https://finance.yahoo.com/news/merck-co-digital-transformation-strategy-091000757.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "0d321736-1d33-3a60-afd3-694f6bb2eca2",
      "content": {
        "id": "0d321736-1d33-3a60-afd3-694f6bb2eca2",
        "contentType": "STORY",
        "title": "Merck & Co Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map",
        "description": "",
        "summary": "Merck's market opportunities lie in its broad biopharmaceutical offerings, targeting oncology, vaccines, and more, alongside extensive veterinary solutions. Its tech-driven innovations, strategic partnerships, and global presence enhance its competitive edge in healthcare and digital transformation initiatives.Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The \"Enterprise Tech Ecosystem Series: Merck & Co., Inc. 2025\" company profile has been added to ResearchAndMarkets.com's offering. The report pro",
        "pubDate": "2026-02-25T09:10:00Z",
        "displayTime": "2026-02-25T09:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-digital-transformation-strategy-091000757.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-digital-transformation-strategy-091000757.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T09:26:52+00:00",
    "headline": "GSK secures potential ‘multi-blockbuster’ drug in $950mn deal",
    "summary": "GSK has reached a near-$1bn deal to acquire 35Pharma, a Canadian biotech that develops drugs for heart and lung diseases, as part of a drive...",
    "url": "https://finance.yahoo.com/news/gsk-secures-potential-multi-blockbuster-092652964.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "636124ce-4be7-3ff3-918d-ac870ff0ddea",
      "content": {
        "id": "636124ce-4be7-3ff3-918d-ac870ff0ddea",
        "contentType": "STORY",
        "title": "GSK secures potential ‘multi-blockbuster’ drug in $950mn deal",
        "description": "",
        "summary": "GSK has reached a near-$1bn deal to acquire 35Pharma, a Canadian biotech that develops drugs for heart and lung diseases, as part of a drive...",
        "pubDate": "2026-02-25T09:26:52Z",
        "displayTime": "2026-02-25T09:26:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gsk-secures-potential-multi-blockbuster-092652964.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gsk-secures-potential-multi-blockbuster-092652964.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^FTSE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T14:57:20+00:00",
    "headline": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
    "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
    "url": "https://finance.yahoo.com/news/large-cap-pharma-defensive-ai-145720870.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "38db119c-9f44-3acf-9b13-4ff354235b4a",
      "content": {
        "id": "38db119c-9f44-3acf-9b13-4ff354235b4a",
        "contentType": "STORY",
        "title": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
        "description": "",
        "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
        "pubDate": "2026-02-25T14:57:20Z",
        "displayTime": "2026-02-25T14:57:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/large-cap-pharma-defensive-ai-145720870.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/large-cap-pharma-defensive-ai-145720870.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T14:00:05+00:00",
    "headline": "Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock",
    "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finance.yahoo.com/news/know-beyond-why-merck-co-140005556.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "54a1b88f-abb1-3529-a285-bd13edf69ed7",
      "content": {
        "id": "54a1b88f-abb1-3529-a285-bd13edf69ed7",
        "contentType": "STORY",
        "title": "Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock",
        "description": "",
        "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
        "pubDate": "2026-02-25T14:00:05Z",
        "displayTime": "2026-02-25T14:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b",
          "originalWidth": 900,
          "originalHeight": 711,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bjs59nqcRE8iEsudL3mMxA--~B/aD03MTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 900,
              "height": 711,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bro_swiyYm6CQ_YbyBgC9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/know-beyond-why-merck-co-140005556.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/know-beyond-why-merck-co-140005556.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T13:49:00+00:00",
    "headline": "Can J&J Sustain Its Double-Digit Oncology Growth Streak?",
    "summary": "JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?",
    "url": "https://finance.yahoo.com/news/j-j-sustain-double-digit-134900028.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "be5ba834-6761-3b02-a211-fbd767222d0d",
      "content": {
        "id": "be5ba834-6761-3b02-a211-fbd767222d0d",
        "contentType": "STORY",
        "title": "Can J&J Sustain Its Double-Digit Oncology Growth Streak?",
        "description": "",
        "summary": "JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?",
        "pubDate": "2026-02-25T13:49:00Z",
        "displayTime": "2026-02-25T13:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-sustain-double-digit-134900028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-sustain-double-digit-134900028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]